MXPA02000779A - Factor de activacion de la citocina altamente purificada y metodos de uso. - Google Patents

Factor de activacion de la citocina altamente purificada y metodos de uso.

Info

Publication number
MXPA02000779A
MXPA02000779A MXPA02000779A MXPA02000779A MXPA02000779A MX PA02000779 A MXPA02000779 A MX PA02000779A MX PA02000779 A MXPA02000779 A MX PA02000779A MX PA02000779 A MXPA02000779 A MX PA02000779A MX PA02000779 A MXPA02000779 A MX PA02000779A
Authority
MX
Mexico
Prior art keywords
methods
highly purified
activating factor
cytokine activating
purified cytokine
Prior art date
Application number
MXPA02000779A
Other languages
English (en)
Inventor
Subramanian Iyer
Original Assignee
Arkion Life Sciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arkion Life Sciences Llc filed Critical Arkion Life Sciences Llc
Publication of MXPA02000779A publication Critical patent/MXPA02000779A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/465—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/85—Reproductive organs or embryos
    • Y10S530/852—Sperm
    • Y10S530/853—Ovary; eggs; embryos
MXPA02000779A 1999-07-23 2000-07-19 Factor de activacion de la citocina altamente purificada y metodos de uso. MXPA02000779A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14531799P 1999-07-23 1999-07-23
US19761900P 2000-04-14 2000-04-14
PCT/US2000/019643 WO2001007472A1 (en) 1999-07-23 2000-07-19 Highly purified cytokine activating factor and methods of use

Publications (1)

Publication Number Publication Date
MXPA02000779A true MXPA02000779A (es) 2003-10-15

Family

ID=26842849

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02000779A MXPA02000779A (es) 1999-07-23 2000-07-19 Factor de activacion de la citocina altamente purificada y metodos de uso.

Country Status (18)

Country Link
US (2) US6420337B1 (es)
EP (1) EP1198475B1 (es)
JP (1) JP4763193B2 (es)
CN (1) CN1376163A (es)
AR (1) AR033340A1 (es)
AT (1) ATE290017T1 (es)
AU (1) AU778239B2 (es)
BR (1) BR0013043A (es)
CA (1) CA2379251A1 (es)
CO (1) CO5290297A1 (es)
DE (1) DE60018426T2 (es)
ES (1) ES2239019T3 (es)
IL (1) IL147716A0 (es)
MX (1) MXPA02000779A (es)
MY (1) MY125980A (es)
NZ (1) NZ516744A (es)
TW (1) TWI250164B (es)
WO (1) WO2001007472A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003216227A1 (en) * 2002-02-11 2003-09-04 Arkion Life Sciences Llc Purified cytokine inhibitory factor
US20040005327A1 (en) * 2002-05-16 2004-01-08 Subramanian Iyer Immune T-cell stimulation
WO2006069779A1 (en) * 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Preparing of peptides with excellent solubility
US20080071067A1 (en) * 2006-09-20 2008-03-20 Avigenics, Inc. Methods of purifying proteins from egg white
US7852810B1 (en) * 2007-01-03 2010-12-14 Sprint Spectrum L.P. Dynamic adjustment of forward-link frame-error-rate (FFER) target
US7813323B1 (en) 2007-06-13 2010-10-12 Sprint Spectrum L.P. Dynamic adjustment of reverse-link frame-error-rate (RFER) target based on reverse-link RF conditions
US8107988B1 (en) 2008-07-25 2012-01-31 Sprint Spectrum L.P. Conducting power control based on reverse-link RF conditions
AU2009289479B2 (en) * 2008-09-05 2014-10-30 Cardiopolymers, Inc. Process for generating microwalled encapsulation balloons
US8477686B1 (en) 2009-09-10 2013-07-02 Sprint Spectrum L.P. Automatic increase of target frame error rate for duration based on call drop timer
US8290532B1 (en) 2010-04-19 2012-10-16 Sprint Spectrum L.P. Selectively conducting reverse-link power control and call admission control
US8537700B1 (en) 2010-04-19 2013-09-17 Sprint Spectrum L.P. Identifying and selectively controlling reverse-noise contribution on a per-access-terminal basis
CN104288769B (zh) * 2014-09-17 2017-09-29 陕西建华生物制药有限公司 一种西药外用膏剂及其制备方法
JP5894695B1 (ja) * 2015-05-25 2016-03-30 ホーユー株式会社 ウズラの卵アレルギーの抗原
US10632158B2 (en) 2016-06-23 2020-04-28 IgY Nutrition Use of a hyperimmune egg product to prevent and treat dysbiosis
WO2018148734A1 (en) 2017-02-13 2018-08-16 The United States Of America, As Represented By The Secretary Of Agriculture Hyperimmunized egg product for treatment of necrotic enteritis in poultry

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119279D0 (en) * 1991-09-10 1991-10-23 Ici Plc Modification of lignin synthesis in plants
WO1998028419A2 (en) * 1996-12-20 1998-07-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for modulation of vesicular release

Also Published As

Publication number Publication date
CO5290297A1 (es) 2003-06-27
NZ516744A (en) 2004-01-30
WO2001007472A1 (en) 2001-02-01
ATE290017T1 (de) 2005-03-15
AR033340A1 (es) 2003-12-17
JP2003506019A (ja) 2003-02-18
AU778239B2 (en) 2004-11-25
EP1198475B1 (en) 2005-03-02
EP1198475A1 (en) 2002-04-24
US6420337B1 (en) 2002-07-16
IL147716A0 (en) 2002-08-14
DE60018426T2 (de) 2006-05-11
AU6110600A (en) 2001-02-13
BR0013043A (pt) 2002-04-30
JP4763193B2 (ja) 2011-08-31
US20030143190A1 (en) 2003-07-31
ES2239019T3 (es) 2005-09-16
EP1198475A4 (en) 2003-05-14
TWI250164B (en) 2006-03-01
MY125980A (en) 2006-09-29
DE60018426D1 (de) 2005-04-07
CA2379251A1 (en) 2001-02-01
CN1376163A (zh) 2002-10-23

Similar Documents

Publication Publication Date Title
MXPA02004770A (es) Composiciones terapeuticas y metodos para su uso.
AU4520801A (en) Novel substituted phenanthridinones and methods of use thereof
EP1283702A4 (en) MEDICAL ASSOCIATION ARRANGEMENT AND METHOD OF THE APPLICATION
HRP20060251B1 (hr) Supstituirani oksazolidinoni i njihova uporaba
PL355867A1 (en) New use and novel n-azabicyclo-amide derivatives
GB9912350D0 (en) Modified cytokine
HUP0200418A3 (en) Human cytokine as ligand of the zalpha receptor and uses thereof
GB9904503D0 (en) Combination desk and chair
AU4289100A (en) Dihydropyrimidines and their use in the treatment of hepatitis
MXPA02000779A (es) Factor de activacion de la citocina altamente purificada y metodos de uso.
HUP0203896A3 (en) Substituted 8-arylquinoline phosphodiesterase-4-inhibitors and use thereof
AU715620C (en) Therapeutic methods and uses
AU3623700A (en) Apoptosis inducing molecule ii and methods of use
EG22491A (en) Rest-breaking composition and use thereof
AU3501700A (en) Human endokine alpha and methods of use
EP1194548A4 (en) NOVEL PYRRHOCORICIN-DERIVED PEPTIDES AND METHODS OF IMPLEMENTING THE SAME
AU2529799A (en) Benzofuran-4-carboxamides and their therapeutic use
AU2669201A (en) Taccalonolides and their use
EP1185286A4 (en) MU O-CONOPEPTIDES AND THEIR USE AS LOCAL ANESTHESICS
AU7684000A (en) Interferon complex and medicinal use thereof
GB9929581D0 (en) Comjpositions and their use
IL146940A0 (en) Novel calpains and their use
AU2001261785A1 (en) Vdup1 promoter and methods of use thereof
EP1210111A4 (en) DNA OF GAMMA HERPESVIRUS AND METHODS OF USE THEREOF
AU2279601A (en) Npr1-interactors and methods of use

Legal Events

Date Code Title Description
FG Grant or registration